BioSpace News Archive

Eccogene announced that the U.S. Food and Drug Administration has approved the investigational new drug application to commence a Phase I trial of its glucagon-like peptide 1 receptor agonist ECC5004 for type 2 diabetes mellitus.

Addex Therapeutics announced that it will issue its third quarter 2022 financial results on Friday, November 11, 2022 and provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET the same day.

Addex Therapeutics announced that it had received written notification from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for the Company’s American Depositary Shares had closed below the minimum US$1.00 per ADS requirement for continued listing on Nasdaq under listing rule 5550.

Samsung Bioepis Co., Ltd. announced the company has won ‘Company of the Year, Asia-Pacific’ at the ‘Global Generics & Biosimilars Awards 2022’ held on November 2, 2022 in Frankfurt, Germany.

In the first nine months of the 2022 financial year, Novozymes delivers 9% organic sales growth, an EBIT-margin of 27.2%, and ROIC including goodwill of 17.8%.

APEIRON Respiratory Therapies GmbH announces positive final results from a Phase I clinical trial of inhaled APN01, a soluble recombinant version of the SARS-CoV-2 cell entry receptor ACE2.

CEOs from AstraZeneca, GSK, Merck KGaA, Novo Nordisk, Roche, Samsung Biologics and Sanofi announced joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.

Evotec SE announced that the acquisition of Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd., signed in August 2022, has been completed.

Biophytis SA released the full results from its phase 2-3 COVA clinical study evaluating Sarconeos in the treatment of COVID-19-related respiratory failure.

Acepodia announced the upcoming poster presentation of new preclinical data for ACE1831, a gamma delta 2 T cell therapy being developed as a treatment for non-Hodgkin’s lymphoma.